Published in Aging and Elder Health Week, June 18th, 2006
The Zomaxx Europe study is a single-arm trial that will evaluate the safety and performance of the Zomaxx zotarolimus-eluting stent in patients with single- or two-vessel coronary artery disease, representing an important step toward broadening the complexity of patients treated with Zomaxx. The study will include approximately 900 patients at up to 60 sites throughout Europe with a primary endpoint of target lesion revascularization (TLR) at 9 months.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Aging and Elder Health Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.